New indication for immunotherapy drug

Nivolumab (Opdivo, Bristol-Myers Squibb) has been approved by the TGA as a monotherapy for patients with advanced clear cell renal cell carcinoma.

The drug can be used in patients after previous anti-angiogenic therapy and is the first immunotherapy to be approved for Australian patients with advanced kidney cancer.

The new indication was approved based on the CheckMate-025 trial which found patients treated with nivolumab